Skip to main content
OpenTrials
Completed

NCT Number: NCT00633009

Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen

The efficacy of LtSTA as a skin test antigen depends upon the sensitivity and specificity of the product. This study has been designed to measure the skin test responses to 15, 30, or 50µg doses of LtSTA. The measurements of non-specific reactivity due to components of the antigen solution and the product's ability to sensitize lymphocytes of Leishmania naïve persons when administered intradermally. The presence or absence of a local inflammatory response to the first skin test with each of three doses of LtSTA will provide insight on the specificity of the antigen in a naïve population. The local inflammatory response to LtSTA following the first and second repeat skin tests will indicate if the antigen is sensitizing after intradermal administration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cutaneous Leishmaniasis Euglenozoa Infections Hypersensitivity Hypersensitivity, Delayed Immune System Diseases Infections Leishmaniasis Leishmaniasis, Cutaneous Parasitic Diseases Protozoan Infections Skin Diseases Skin Diseases, Infectious Skin Diseases, Parasitic Skin and Connective Tissue Diseases Vector Borne Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

California Research Foundation

San Diego, California, 92103-6204, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or Female in good health;
  • Age 18 - 60 years;
  • No past history of leishmaniasis or prior participation in a Leishmania study;
  • No prior skin test with a Leishmania antigen;
  • No occupational, residential, or travel exposure to Leishmania;
  • Positive Candin® or Trichophyton skin test (>= 5 mm induration).

Exclusion criteria

  • History of adult atopic dermatitis, contact dermatitis to multiple agents, unexplained urticaria, or asthma;
  • Active allergic rhinitis or conjunctivitis;
  • History of allergy or reactions to phenol, polysorbate 80, or glycerol;
  • Medications: currently taking (within the last month) antihistamines or recent history of taking (within the last 1 year) corticosteroids, immunosuppressants;
  • Splenectomy;
  • Active medical disease*;

*Active Medical Disease: Any active physical or psychiatric condition that may increase the risks associated with participation in the study or interferes with the interpretation of study results. Included chronic medical illnesses are cardiovascular disease, renal insufficiency, chronic respiratory illness, cirrhosis, chronic hepatitis, chronic pancreatitis, chronic diarrhea, malnutrition, malignancy, autoimmune disease, and asthma.

  • Pregnancy or lactating;
  • Immunization within 4 weeks;
  • History of leishmaniasis;
  • Occupational exposure to Leishmania;
  • Prior participation in a Leishmania study;
  • Prior skin test with Leishmania antigen;
  • Travel history to Leishmania endemic areas;
  • Abnormal screening lab results;
  • Keloid scar formation

Treatment and study plan

Leishmania tropica Skin Test Antigen (LtSTA)

Biological

Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.

Leishmania tropica Skin Test Antigen Placebo (Placebo)

Biological

Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo

Primary outcomes

  1. Sensitizing Effects of LtSTA in Leishmania Naive Adults

    Time frame: 62 days

    Skin test response of subjects in the trial were evaluated 48 hours post injection after each of three skin test given at 30 day intervals in naive individuals (no exposure to the Leishmania organism). (Actual times 0, 30 and 60 days).The outcome measure was designated as number of participants who became sensitized to the Leishmania antigen. This is defined as those participants that had a negative skin test result, followed by a positive response in a subsequent skin test without having been exposed to the Leishmania organism.

Secondary outcomes

  1. The Safety of 15, 30 and 50µg/0.1mL Doses of LtSTA in Healthy Adult Volunteers Who Have Had no Known Previous Exposure to Leishmania Parasites

    Time frame: 74 days

    Local and systemic events following skin test. Local: burning, itching, pain. Systemic: Body aches, dizziness, nausea, weakness.

Sponsors and collaborators

Lead sponsor

Nielsen BioSciences, Inc.

Industry

Collaborators

  • U.S. Army Medical Research and Development Command

Registry information

Official study title

A Blinded, Placebo Controlled Study Evaluating Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen (LtSTA)

Important dates

Study start
2008
Primary completion
2009
Study completion
2010
First posted
Mar 11, 2008
Registry last updated
Nov 20, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.